Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.49 |
| ▸ | ASAH1 | Q13510 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651781 | 0.83 | GPR84 (0.50) | GPR84ASAH1LMNACYP3A4CYP2D6 | |
| SCHEMBL16652498 | 0.81 | MEN1 (0.48) | GPR84ASAH1LMNACYP3A4CYP2D6 | |
| SCHEMBL15538232 | 0.72 | ASAH1 (0.54) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL7784441 | 0.72 | ASAH1 (0.61) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL15538393 | 0.69 | ASAH1 (0.71) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL2071214 | 0.69 | ASAH1 (0.57) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL19147831 | 0.68 | ASAH1 (0.74) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL15539184 | 0.68 | ASAH1 (0.74) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL5304437 | 0.68 | ASAH1 (0.56) | ASAH1LMNACYP3A4CYP2D6MAPK3 | |
| SCHEMBL2072861 | 0.68 | ASAH1 (0.47) | ASAH1LMNACYP3A4CYP2D6MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428465-B2 | Acid ceramidase inhibitors and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2016-08-30 | — | — | US | disclosed |
| US-20150111892-A1 | ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111892-A1 | ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | GPR84 1949/4885ASAH1 1/4885LMNA 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.